Trial Profile
A Phase III,Multicentre, Randomized, Double-Blind and Open-Label Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Idiopathic Thrombocytopenic Purpura
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jan 2023
Price :
$35
*
At a glance
- Drugs Hetrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 13 Dec 2022 Results of a post-hoc analysis assessing response in patients who switched from eltrombopag to hetrombopag presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 02 Aug 2022 Status changed from recruiting to completed.
- 25 Nov 2021 Results (n=339) assessing the comprehensive data on a < 6-week dose tapering to withdrawal Stage 3 and an additional 24-week long-term extension period Stage 4, published in the Journal of Thrombosis and Haemostasis.